Search

Search Results

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?

  Fabienne McClanahan, Peter Dreger

  e2012071

  2012-11-06

  https://doi.org/10.4084/mjhid.2012.071

  2387

  PDF: 801

  HTML: 1653

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2644

  PDF: 1638

  HTML: 250

• MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

  Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan

  e2015001

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.001

  2249

  PDF: 1316

  HTML: 17067

  Bassan Fig.1: 137

  Bassan Fig.2: 144

  Bassan Fig.4: 132

  Fig.3: 176

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2221

  PDF: 927

  HTML: 2357

• CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,

  Ugo Testa, Giuseppe Leone, Elvira Pelosi, Dr. Germana Castelli, Prof. Hohaus

  e2023066

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.066

  3634

  PDF: 1415

  HTML: 172

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  3975

  PDF: 1032

  HTML: 3572

  Untitled: 171

  Cneo. Fig.1: 107

  Untitled: 97

  Untitled: 122

  Untitled: 125

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4376

  PDF: 1608

  HTML: 3553

  Tables and Images: 210

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1299

  HTML: 116

  PDF: 848

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4274

  PDF: 1472

  HTML: 1537

  Untitled: 218

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1652

  PDF: 1629

  HTML: 777

• INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  AnnaMaria Nosari

  e2012070

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.070

  3251

  PDF: 1332

  HTML: 2618

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2672

  PDF: 3162

  HTML: 358

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7373

  PDF: 2393

  HTML: 1713

  Table 1.: 198

  Table 2.: 211

  Table 3.: 191

  Table 4.: 190

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4271

  PDF: 1466

  HTML: 3605

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2444

  PDF: 1958

  HTML: 193

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1991

  PDF: 1106

  HTML: 171

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1214

  PDF: 780

  HTML: 530

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1339

  HTML: 379

  PDF: 808

• Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.

  Emanuele Cencini, Alberto Fabbri, Umberto Arrigucci, Alfonso Cerase, Monica Bocchia

  e2017040

  2017-06-16

  https://doi.org/10.4084/mjhid.2017.040

  3276

  PDF: 1013

  HTML: 993

  Figure 1: 167

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1492

  PDF: 871

  HTML: 104

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2458

  PDF: 831

  HTML: 8802

  Efremov 1: 216

  Efremov 2: 177

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3488

  PDF: 2380

  HTML: 1438

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3695

  PDF: 1047

  HTML: 1911

• CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.

  Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Nicola Piccirillo, Tommaso Za, Silvia Bellesi, Sara Marietti, Simona Sica, Dimitar G. Efremov, Giuseppe Leone

  e2013031

  2013-05-01

  https://doi.org/10.4084/mjhid.2013.031

  3108

  PDF: 883

  HTML: 1527

  Fig.1 CHL-R paper: 207

  Fig 2 CHL-R paper: 230

• PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries

  Dr, Moleti, Anna Maria Testi

  e2024078

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.078

  1220

  PDF: 837

  HTML: 271

• HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS: LOW INCIDENCE OF PRIMARY NEOPLASM AS A TRIGGER IN A CASE SERIES FROM TURKEY

  Ferhat Arslan

  e2018047

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.047

  1524

  PDF: 885

  HTML: 212

  Figure 1: 163

• Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

  Giovanni Manfredi Assanto ,, Matteo Totaro , Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, Giuseppe Gentile

  e2023061

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.061

  758

  PDF: 407

  HTML: 105

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4007

  PDF: 1135

  HTML: 1924

  Fig.1: 212

  Fig. 2: 105

  Table 1: 198

  Table2: 212

  Table 3: 194

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1641

  PDF: 638

  HTML: 2422

• COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA

  Antonio Frolli, Cristina Papayannidis, Carmen Fava, Martina Bullo, Selene Grano, Valentina Bonuomo, Daniela Gottardi, Guido Parvis, Beatrice Casadei, Daniela Cilloni

  e2026047

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.047

  93

  PDF: 111

  HTML: 7

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS

  Giuseppe Visani, Paola Picardi, Patrizia Tosi, Alessandro Isidori

  e2012075

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.075

  2493

  PDF: 863

  HTML: 2111

• LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.

  Andrea Riccardo Filippi

  e2016041

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.041

  3671

  PDF: 1074

  HTML: 2272

  Figure 1: 205

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3467

  PDF: 1513

  HTML: 68

• CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA

  Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Luana Fianchi

  e2009030

  https://doi.org/10.4084/mjhid.2009.030

  1255

  PDF: 603

  HTML: 3065

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN FOLLICULAR LYMPHOMAS

  Mónica Cabrero, Alba Redondo, Alejandro Martin, Dolores Caballero

  e2012074

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.074

  2126

  PDF: 720

  HTML: 1059

• CIRCCTNNA1 IS UPREGULATED IN MANTLE CELL LYMPHOMA AND PREDICTS POOR SURVIVAL BY SPONGING MIR-34A TO INCREASE CELL PROLIFERATION.

  Xuebing Jing, Cong Lu, Chao Song, Qingkun Han

  e2022047

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.047

  623

  PDF: 492

  HTML: 209

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3335

  PDF: 1268

  HTML: 2202

  Fi.1 Gritti.Rambaldi: 199

• Is laboratory monitoring useful in DOACs management?

  Mario Biglietto, Rosaria Mormile, Matteo Totaro, Maria Laura Bisegna, Cristina Santoro, Antonio Chistolini

  e2025019

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.019

  807

  PDF: 786

  HTML: 101

• Burkitt lymphoma as fourth neoplasia in a patient affected by Cowden Syndrome with a novel PTEN germline pathogenic variant

  Eugenio Galli, Francesco D’Alò, Annarosa Cuccaro, Eleonora Alma, Elena Maiolo, Fulvia Brugnoletti, Luigi Maria Larocca, Marcella Zollino, Andrea Paolo Bacigalupo, Stefan Hohaus

  e2020034

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.034

  1223

  PDF: 590

  HTML: 202

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2209

  PDF: 1782

  HTML: 132